ArticleCancer cell international2026
ANKRD49 promotes the epithelial-mesenchymal transition of non-small cell lung cancer via the PKNOX1/TGF-β1/SMAD axis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANKRD49 promotes immune evasion in lung adenocarcinoma by activating the MEF2A/PD‑L1 axis.Biology direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAnkyrin repeat domain 49 (ANKRD49) is highly expressed in non-small cell lung cancer (NSCLC) and promotes tumor cell invasion and metastasis by activating the p38/ATF-2/MMP or JNK/ATF-2/c-Jun/MMP pathways. Although epithelial-mesenchymal transition (EMT) is critical for tumor dissemination, the role of ANKRD49 in EMT remains unclear. This study aimed to investigate the effects of ANKRD49 on EMT in NSCLC and to elucidate its underlying molecular mechanisms.
methodsThe expression levels of ANKRD49 and EMT markers were analyzed in lung adenocarcinoma (LUAD) tissues using tissue microarrays (TMAs) combined with immunohistochemistry (IHC). The role of ANKRD49 in EMT was assessed in vitro and in vivo through real-time qPCR, Western blot, and IHC. Key signaling molecules were quantified by real-time qPCR, Western blot, enzyme-linked immunosorbent assay (ELISA) and IHC. Transcriptional regulation of TGF-β1 by PKNOX1 was verified using luciferase reporter assays and chromatin immunoprecipitation (ChIP). Protein-protein interactions between ANKRD49 and PKNOX1 were examined by co-immunoprecipitation (Co-IP) and immunofluorescence microscopy.
resultsTMA analysis revealed a significant negative correlation between ANKRD49 and E-cadherin expression, whereas positive correlations were observed with α-smooth muscle actin (α-SMA) and TGF-β1. ANKRD49 overexpression promoted EMT, whereas its knockdown suppressed EMT in both cellular and animal models. Furthermore, ANKRD49 upregulation increased TGF-β1 levels, which are transcriptionally regulated by PKNOX1, while ANKRD49 silencing had the opposite effect. Mechanistically, ANKRD49 physically interacts with PKNOX1, and PKNOX1 binds to the TGF-β1 promoter, elevating TGF-β1 expression and subsequently activating SMAD signaling. Consistently, ANKRD49 and PKNOX1 levels were positively correlated in LUAD tissues.
conclusionANKRD49 facilitates EMT in NSCLC by interacting with PKNOX1 to activate the TGF-β1/SMAD pathway. PKNOX1 mediates this process through transcriptional regulation of TGF-β1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.